Swiss drugmaker Roche Holding on Monday named Eli Lilly executive Levi Garraway to succeed Sandra Horning as chief medical officer and head of global product development.
Garraway, most recently Eli Lilly’s senior vice president, oncology research and development and Lilly research laboratories novel target research, will take up the post as of Oct. 1 and be based in South San Francisco.
Horning, who joined Roche and its Genentech division nearly a decade ago and has been chief medical officer since 2014, will retire as of the end of 2019, Roche said in a statement.
She led the product development organization, oversaw late-stage clinical development, and co-chaired the committee that invests in pivotal registrational trials.
Garraway joined Lilly in 2017 as senior vice president, global development and medical affairs for the oncology division. Before that he was director of the Joint Center for Cancer Precision Medicine, which spanned Harvard teaching hospitals.
In 2010, Garraway, a Harvard graduate, co-founded Foundation Medicine, which provides tumor molecular information.
By John Miller
LinkedIn Twitter FacebookAccording to information procured exclusively ahead of a formal announcement Friday, a subsidiary of NYSE-traded giant Teva Pharmaceuticals has signed a deal with medical cannabis company Canndoc to […]
LinkedIn Twitter FacebookA document published by the UK Government laying out the worst case scenario if the UK leaves the European Union (EU) with no deal on 31st October stated […]
LinkedIn Twitter FacebookVifor Pharma is losing a chief commercial officer but gaining a new chief medical officer in the form of Sanofi’s Klaus Henning Jensen. Jensen joins from the French […]